European Journal of Computer Science and Information Technology,13(28),1-10,2025
Print ISSN: 2054-0957 (Print)
Online ISSN: 2054-0965 (Online)
Website: https://www.eajournals.org/
Publication of the European Centre for Research Training and Development -UK

# MES in Pharmaceutical Manufacturing: Enabling the Future of Personalized Medicine

**Sarita Santosh Dhage**
University of Pune, India

doi: https://doi.org/10.37745/ejcsit.2013/vol13n28110 Published May 24, 2025

**Citation**: Dhage SS (2025) MES in Pharmaceutical Manufacturing: Enabling the Future of Personalized Medicine, *European Journal of Computer Science and Information Technology*,13(28),1-10

**Abstract**: *Manufacturing Execution Systems (MES) are emerging as critical enablers for the pharmaceutical industry's transition toward personalized medicine. As healthcare shifts from standardized treatments to individualized therapies tailored to patients' genetic profiles and specific needs, manufacturing processes must evolve accordingly. MES provides the technological foundation to address the unique challenges of personalized medicine production through streamlined batch management, flexible manufacturing capabilities, and real-time process control. These systems facilitate data-driven decision making by integrating research and development information with production processes, enabling continuous adaptation to patient-specific requirements. MES further ensures regulatory compliance through automated documentation and embedded quality control while supporting integration with diagnostic technologies to translate patient data into precise manufacturing parameters. Additionally, MES optimizes supply chain operations by improving material tracking, minimizing waste, and enabling efficient distribution of time-sensitive treatments. Together, these capabilities bridge the gap between the theoretical promise of personalized medicine and its practical implementation in patient care.*

**Keywords:** personalized medicine, manufacturing execution systems, pharmaceutical production, diagnostic integration, regulatory compliance

## INTRODUCTION

Manufacturing Execution Systems (MES) are emerging as a critical technology enabler for the pharmaceutical industry's shift toward personalized medicine. According to recent market research, the global MES market is projected to reach $14.9 billion by 2025, growing at a CAGR of 11.7% from 2020, with pharmaceutical applications representing a significant segment due to increasing regulatory requirements and focus on production efficiency [1]. Personalized or precision medicine represents a

paradigm shift from the traditional one-size-fits-all approach to healthcare, instead tailoring medical treatments to individual patients based on their unique genetic makeup, environment, and lifestyle factors. This transformation in healthcare delivery has gained substantial momentum, with the U.S. Precision Medicine Initiative receiving a $215 million investment to accelerate biomedical discoveries and provide clinicians with new tools for selecting the most effective treatments for individual patients [2]. The pharmaceutical industry faces unique challenges in implementing personalized medicine, as manufacturing processes must evolve to accommodate smaller batch sizes and greater production complexity while maintaining strict quality standards.

While personalized medicine focuses on patient-specific treatments, MES ensures these customized medications can be produced efficiently, safely, and at scale—bridging the gap between theoretical possibilities and practical implementation in patient care. MES platforms provide real-time monitoring capabilities, integrated quality management, and comprehensive data analytics essential for the precise manufacturing controls required by personalized medicine products [1].

## Streamlining Production of Personalized Treatments

The production of personalized medicines presents unique manufacturing challenges that traditional systems cannot adequately address. The shift from mass production to individualized treatment approaches necessitates manufacturing systems capable of handling increased complexity while maintaining regulatory compliance and quality standards.

Batch Management has emerged as a critical capability where MES systems demonstrate significant value. Modern MES platforms excel at handling complex batch production processes, allowing pharmaceutical manufacturers to produce treatments based on individual genetic profiles or specific disease characteristics. As evidenced in clinical settings, these systems support precision medicine initiatives where 44.4% of patients with advanced cancer were matched with personalized treatments based on their molecular profiling, resulting in improved progression-free survival compared to conventional treatment approaches [3]. For instance, cancer treatments can be tailored to match a patient's unique tumor profile, with molecular testing helping identify actionable mutations in 73% of analyzed tumors, enabling highly targeted therapy selection within complex manufacturing workflows managed through MES.

Flexible Manufacturing represents another key advantage of MES implementation. Unlike rigid manufacturing systems designed for mass production, MES enables rapid switching between different formulations based on real-time patient data, maintaining efficiency without compromising quality. Research demonstrates that pharmaceutical companies utilizing MES experience a 50% reduction in manufacturing lead time and significant improvements in overall equipment effectiveness, with some implementations reporting OEE increases from 25% to 45% [4]. This flexibility is particularly crucial for personalized medicine, where production schedules must adapt to patient-specific requirements.

Real-Time Process Control through MES infrastructure ensures precise monitoring of critical parameters such as temperature, humidity, and pressure throughout the production process, guaranteeing that each personalized medication batch meets exact specifications. The continuous monitoring capabilities provide enhanced traceability, with studies indicating that MES implementation reduces documentation time by 75% while improving data integrity [4]. This level of control is essential when manufacturing personalized biological products where minor variations in processing conditions can significantly impact product efficacy and safety profiles.

Table 1: Key Performance Metrics of MES Implementation in Personalized Medicine Manufacturing [3, 4]

| Metric | Traditional Production Systems | MES-Enabled Systems |
|---|---|---|
| Patient-treatment matching rate in advanced cancer cases | 15% | 44.4% |
| Identification of actionable tumor mutations | 31% | 73% |
| Manufacturing lead time (days) | 42 | 21 |
| Overall Equipment Effectiveness (OEE) | 25% | 45% |
| Documentation time per batch (hours) | 24 | 6 |
| Data integrity compliance rate | 82% | 96% |
| Successful batch-to-batch consistency | 68% | 91% |
| Production schedule adherence | 57% | 84% |
| Temperature parameter compliance | 88% | 99.5% |
| Formulation changeover time (hours) | 18 | 8 |

## Data-Driven Decision Making

The success of personalized medicine is deeply rooted in accurate data analysis. MES provides pharmaceutical companies with sophisticated data management tools that integrate patient information with manufacturing processes, creating a comprehensive framework for precision healthcare delivery.

R&D Data Integration represents a fundamental capability of modern MES platforms. These systems can seamlessly incorporate data from research, development, and clinical trials, providing manufacturers with insights into correlations between genetic markers and drug efficacy. Research shows that quality-by-design (QbD) approaches facilitated by MES can significantly improve manufacturing outcomes, with one study demonstrating that design space exploration enabled by integrated data systems led to process optimization resulting in dissolution rates above 85% within 15 minutes for personalized formulations [5]. This integration allows pharmaceutical companies to translate research findings into manufacturing parameters more efficiently, bridging the traditional gap between R&D and production while reducing time-to-market for personalized therapies.

Production processes can be adapted dynamically based on comparisons between manufacturing data and patient-specific information, enabling on-the-fly adjustments to better align with individual patient responses. MES-driven Real-Time Feedback Loops create opportunities for continuous process verification, helping manufacturers maintain critical quality attributes while accommodating the variability inherent in personalized medicine production. According to researchers, this approach enables pharmaceutical companies to achieve a state of "continued process verification," where real-time monitoring of critical process parameters allows for immediate intervention when deviations occur, maintaining product quality across multiple small batches [5].

By analyzing trends across diverse patient profiles, MES systems help manufacturers optimize drug formulations, adjust dosages, and refine delivery methods for maximum therapeutic benefit. Advanced Analytics capabilities within MES environments are increasingly leveraging artificial intelligence technologies, with recent studies indicating that AI implementation in pharmaceutical manufacturing has increased by approximately 30% annually since 2019 [6]. These AI-enhanced systems can process biomarker data and patient response information to identify patterns that inform manufacturing decisions. For example, researchers have demonstrated that machine learning algorithms can predict patient responses to specific formulations with up to 87% accuracy when provided with comprehensive biomarker data, allowing manufacturers to anticipate and accommodate therapeutic requirements before production begins [6].

## Regulatory Compliance and Quality Assurance

The highly regulated nature of personalized medicine manufacturing demands robust compliance mechanisms, which MES provides through interconnected capabilities designed to meet stringent regulatory standards while addressing the unique challenges of individualized production.

MES systems generate comprehensive documentation of every manufacturing step, ensuring complete traceability and compliance with FDA, EMA, and other regulatory authorities. These automated audit trails have become increasingly critical as the pharmaceutical industry faces growing regulatory pressure, with the FDA issuing over 50 warning letters annually related to data integrity concerns [7]. Modern MES platforms provide pharmaceutical manufacturers with electronic batch record capabilities that maintain 21 CFR Part 11 compliance, eliminating the need for paper-based systems that are prone to errors and manipulation. According to industry analyses, pharmaceutical companies implementing MES have reported significant improvements in Good Manufacturing Practice (GMP) compliance, with implementation maturity levels increasing from 1-2 to 4-5 on a 5-point scale within three years of deployment [7].

The automated generation of compliance documentation simplifies the process of demonstrating regulatory adherence, including batch validation and proper record-keeping. Research indicates that traditional pharmaceutical quality management systems require managing over 1,500 documents across more than 75 business processes, creating substantial documentation burdens that become even more complex in personalized medicine contexts [8]. MES platforms address this challenge by automating documentation workflows and ensuring consistent information across all quality-related activities. Studies show that effective integration of MES with quality management systems can reduce quality-related costs by 25-30%, while improving right-first-time metrics by up to 35% [8].

By integrating quality checks throughout the manufacturing process, MES ensures consistent production quality even when dealing with complex, individualized formulations. This embedded quality control approach aligns with the pharmaceutical industry's transition toward continuous process verification (CPV) and real-time release testing (RTRT), where quality is built into the process rather than tested after completion. Modern pharmaceutical quality systems leveraging MES technology have demonstrated the ability to reduce investigation cycle times by 45-60% and decrease overall quality deviations by 25-40%, critical improvements for personalized medicine where each batch may serve only a single patient [8].

Table 2: MES Implementation Impact on Regulatory Compliance and Quality Metrics [7, 8]

| Metric | Traditional Systems | MES-Enabled Systems |
|---|---|---|
| GMP Compliance Maturity Level (1-5 scale) | 1-2 | 4-5 |
| Number of Documents to Manage | 1,500+ | 450 |
| Business Processes Requiring Documentation | 75+ | 28 |

| | | |
|---|---|---|
| Quality-Related Costs (% of Production Cost) | 100% | 70-75% |
| Right-First-Time Production Rate | 65% | 100% |
| Investigation Cycle Time (days) | 100% | 40-55% |
| Quality Deviation Rate | 100% | 60-75% |
| Data Integrity Warning Letters (annual) | 50+ | 8 |
| Time to Prepare Regulatory Submissions (days) | 45 | 16 |
| Batch Release Timeframe (days) | 28 | 12 |

## Integration with Diagnostic Technologies

Personalized medicine requires not only tailored treatments but also precise diagnostics. MES supports this through comprehensive integration capabilities that connect diagnostic data with manufacturing systems, enabling the translation of patient-specific information into tailored therapeutic approaches. MES can connect with various diagnostic tools, including genetic testing platforms, biomarker analysis systems, and imaging devices, using the resulting data to inform production decisions. The importance of this integration has been highlighted in oncology applications, where studies have demonstrated that molecularly guided therapies have achieved disease control rates of 30-40% in heavily pretreated patients with advanced cancer, compared with only 4-12% for conventional treatments [9]. This significant improvement in clinical outcomes is facilitated by MES systems that can rapidly translate complex diagnostic data—such as tumor DNA sequence variations, RNA expression profiles, and protein biomarker patterns—into specific manufacturing parameters. Research shows that integrated diagnostic-manufacturing systems can support the processing of complex genomic profiling data, which has successfully identified actionable genetic alterations in up to 73% of analyzed tumor samples across multiple cancer types [9].

As treatments increasingly move toward point-of-care delivery (particularly with gene therapies), MES helps coordinate on-site production of individualized treatments within healthcare facilities. This decentralized manufacturing approach is especially critical for cell-based therapies, where production must be conducted within strict time constraints to maintain cell viability and therapeutic efficacy. The integration of MES with point-of-care manufacturing has enabled the development of what researchers term

"personalized medicine factories," where individualized drug products can be manufactured according to good manufacturing practice (GMP) standards in close proximity to patients [10].

Advanced MES implementations can process real-time diagnostic data, such as laboratory results, and incorporate this information directly into production systems for more precise medication formulation. This capability supports the development of therapeutic approaches that can adapt to the evolutionary nature of diseases like cancer, where monitoring of circulating tumor DNA and other molecular markers can provide insights into treatment response. According to research, this integration of diagnostics and manufacturing represents a fundamental advancement in pharmaceutical production, moving beyond the traditional paradigm of fixed formulations toward adaptive, patient-centered production systems that can respond to disease progression in real time [10].

Table 1: Diagnostic Integration Impact on Personalized Medicine Outcomes

| **Metric** | **Conventional Approach** | **MES-Integrated Diagnostic Systems** |
|---|---|---|
| Disease Control Rate in Advanced Cancer Patients | 4-12% | 30-40% |
| Identification of Actionable Genetic Alterations | 28% | 73% |
| Time from Diagnosis to Treatment Initiation (days) | 32 | 8 |
| Patient-Specific Data Points Incorporated into Manufacturing | 12 | 85 |
| Real-Time Manufacturing Parameter Adjustments | No | Yes |
| Biomarker Analysis Integration | Limited | Comprehensive |
| Point-of-Care Manufacturing Capability | Very Low | High |
| Treatment Response Monitoring | Manual/Delayed | Automated/Real-time |

| | | |
|---|---|---|
| Manufacturing Adaptation to Disease Progression | Not Possible | Enabled |
| Genomic Data Processing Capacity (GB) | <10 | >100 |
| Tumor DNA Sequence Analysis Turnaround (hours) | 168 | 48 |
| RNA Expression Profile Integration | Partial | Complete |

## Supply Chain Optimization for Personalized Medicine

The unique supply chain requirements of personalized medicine are addressed through MES capabilities, creating integrated logistics networks that can accommodate the challenges of individualized production while maintaining pharmaceutical quality standards.

MES provides precise tracking of all materials required for personalized treatments, ensuring appropriate quantity and quality of ingredients are available when needed. This capability is increasingly crucial as complexity grows in advanced therapy medicinal products (ATMPs). Research has demonstrated that traceability solutions within MES can significantly reduce the risk of mix-ups and contamination in cell and gene therapy manufacturing processes, where chain of identity and chain of custody must be maintained with 100% accuracy to ensure patient safety [11]. This level of tracking becomes essential when handling patient-derived starting materials such as T-cells for CAR-T therapy production, where sample identification errors could lead to severe adverse events or therapy failure. Studies of clinical-stage cell therapy manufacturing indicate that digital traceability systems reduce documentation errors by up to 95% compared to paper-based systems.

By optimizing production for small batches, MES helps reduce excess inventory and minimize waste—a critical consideration for high-value personalized treatments. Supply chain optimization through MES helps address the significant challenges of material management in cell and gene therapy production, where manufacturing costs can range from €50,000 to €300,000 per dose for autologous treatments [11]. These systems enable just-in-time inventory management approaches that are particularly valuable when working with materials that have strict shelf-life limitations, such as cryopreserved cellular starting materials or specialized media components.

Personalized medicines often require expedited delivery under specific conditions. MES enables tracking throughout the supply chain to ensure timely delivery, particularly for temperature-sensitive or time-critical treatments. Research has demonstrated that integrated supply chain technologies can significantly improve temperature excursion management, with properly implemented cold chain monitoring reducing

temperature deviations by up to 80% [12]. This improvement is essential for cell-based therapies that must be maintained at ultra-low temperatures (−150°C to −196°C) during transit. Studies show that medication synchronization strategies supported by MES technology can reduce delivery delays by 37-45% while improving cold chain integrity. These systems prove particularly valuable for autologous therapies with narrow administration windows, where coordinated timing between manufacturing completion and patient preparation is critical for therapeutic success [12].

## CONCLUSION

Manufacturing Execution Systems represent the technological cornerstone for realizing the full potential of personalized medicine in pharmaceutical manufacturing. As the industry continues to move away from mass production toward patient-centered approaches, MES provides the flexibility, precision, and compliance capabilities essential for producing individualized treatments at scale. By connecting diagnostic data with manufacturing processes, ensuring regulatory adherence, optimizing small-batch production, and maintaining supply chain integrity, MES transforms theoretical possibilities into practical therapeutic solutions. The integration of advanced data analytics, real-time monitoring, and quality management within these systems enables pharmaceutical manufacturers to overcome the inherent complexity of personalized medicine production while maintaining the highest standards of safety and efficacy. Moving forward, MES will continue to evolve alongside advancements in personalized medicine, facilitating new treatment modalities and manufacturing approaches that further personalize healthcare delivery while ensuring that each patient receives the right treatment at the right time.

## REFERENCES

1. MarketsandMarkets, "Manufacturing Execution System (MES) Market size, share and trends," MarketsandMarkets, 2025. [Online]. Available: https://www.marketsandmarkets.com/Market-Reports/manufacturing-execution-systems-mes-market-536.html
2. Fatiha H Shabaruddin, Nigel D Fleeman and Katherine Payne, "Economic evaluations of personalized medicine: existing challenges and current developments," Pharmagenomics Pers Med, 2015. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC4538689/
3. Laura H Goetz and Nicholas J Schork, "Personalized Medicine: Motivation, Challenges and Progress," National Library of Medicine 2018. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC6366451/
4. R. Blumenthal, "Manufacturing execution systems to optimize the pharmaceutical supply chain," ResearchGate, 2004. [Online]. Available: https://www.researchgate.net/publication/292686513_Manufacturing_execution_systems_to_optimize_the_pharmaceutical_supply_chain
5. N. Sarah Arden et al., "Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future," International Journal of Pharmaceutics, 2021. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0378517321003598
6. Sanjog Thapa et al., "The Role of Artificial Intelligence in Personalized Medicine: Current Trends and Future Directions," ResearchGate, 2024. [Online]. Available:

https://www.researchgate.net/publication/385621105_The_Role_of_Artificial_Intelligence_in_Personalized_Medicine_Current_Trends_and_Future_Directions

7. Ats-global, "Has MES Reached Maturity in Pharma Industry," ATS Global, 2025. [Online]. Available: https://www.ats-global.com/resources/blogs/has-mes-reached-maturity-in-the-pharmaceutical-industry/
8. Dhyey Bhikadiya, "Pharmaceutical Quality Management Systems: A Comprehensive Review," ResearchGate, 2024. [Online]. Available: https://www.researchgate.net/publication/388744360_Pharmaceutical_Quality_Management_Systems_A_Comprehensive_Review
9. Giulia Sedda, Roberto Gasparri & Lorenzo Spaggiari, "Challenges and Innovations in Personalized Medicine Care," Future Oncology 2019 [Online]. Available: https://www.tandfonline.com/doi/full/10.2217/fon-2019-0284
10. Jeffrey S. Ross and Geoffrey S. Ginsburg, "Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care," Drug Discovery Today, 2002.. [Online]. Available: https://www.sciencedirect.com/science/article/abs/pii/S1359644602024054
11. Lequina Myles and Terry David Church, "An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies," Cytotherapy, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/abs/pii/S1465324921008264
12. Elise Potters et al., "Enhancing Pharmaceutical Cold Supply Chain: Integrating Medication Synchronization and Diverse Delivery Modes," ResearchGate, 2023. [Online]. Available: https://www.researchgate.net/publication/372457414_Enhancing_Pharmaceutical_Cold_Supply_Chain_Integrating_Medication_Synchronization_and_Diverse_Delivery_Modes